Efficacy and Safety of Second-Line Cabozantinib After IO-IO Versus IO-TKI Combination Therapy and the Impact of Reduced Starting Dose in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Clinical Genitourinary Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles